ceftriaxone + linezolid + meropenem

This is a combination of three antibiotics—ceftriaxone, linezolid, and meropenem—used together for the treatment of severe or resistant bacterial infections.

• Ceftriaxone is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis and death. It is active against many Gram-negative and some Gram-positive bacteria.
• Linezolid is an oxazolidinone antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex in bacterial translation. It is primarily used for multi-resistant Gram-positive infections such as MRSA and VRE.
• Meropenem is a carbapenem antibiotic with broad-spectrum activity against both Gram-negative and Gram-positive bacteria; it also acts by inhibiting cell wall synthesis through binding to penicillin-binding proteins. Meropenem is often reserved for severe or high-risk infections due to its potency against resistant organisms.

The combination may be considered in cases where multidrug-resistant organisms are suspected or confirmed, particularly in critically ill patients (e.g., sepsis, meningitis) when monotherapy may not be sufficient or when synergistic effects are desired.